Details of the Drug Combination

General Information of Drug Combination (ID: DC52MGE)

• Drug Combination Name: DFN-15 + Hepzato
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  DFN-15 (DM3BF9B): N.A.
  Hepzato (DM2AZPP): N.A.
• High-throughput Screening Result:
  Testing Cell Line: HT29
  Zero Interaction Potency (ZIP) Score: 7.28
  Bliss Independence Score: 9.75
  Loewe Additivity Score: 4.54
  LHighest Single Agent (HSA) Score: 1.51

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Carcinoma	DCOM1GF	RXF 393	Investigative	[4]
Adenocarcinoma	DC6352A	OVCAR3	Investigative	[1]
Lung adenocarcinoma	DCAAE55	MDA-MB-231	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [4] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.